Eculizumab, a monoclonal antibody binding C5, inhibiting its cleavage, and thus preventing formation of C5b-9, is used to treat aHUS and some cases of lupus nephritis, C3 glomerulonephritis, dense deposit disease, IgA nephropathy, and transplant rejection (10–17). This evidence concerns the gene C5 and dense deposit disease.